New Retina Radio
New Retina Radio

02.11.22

Exploring the clinical development program for an innovative, continuous delivery treatment for nAMD

Recently, the first refillable, intraocular device that enables continuous delivery of therapy was FDA approved for nAMD. John Kitchens, MD sits down with one of the investigators, Dante Pieramici, MD, to learn more about his experiences with the clinical development program and this innovative drug delivery system. This special episode of New Retina Radio is supported by Genentech USA, Inc., which is responsible for its content.

View full description +

MORE EPISODES

11.25.25

Global Discussions in GA: Educating Patients and Encouraging Follow-Up

Anat Loewenstein, MD; Jordi Monés, MD, PhD; Sobha Sivaprasad, MD; and Giovanni Staurenghi, MD

11.25.25

Global Discussions in GA: Referral Patterns and Fellow-Eye Monitoring

Anat Loewenstein, MD; Jordi Monés, MD, PhD; Sobha Sivaprasad, MD; and Giovanni Staurenghi, MD

11.21.25

Endophthalmitis Rates With and Without Antibiotic Prophylaxis

Sruthi Arepalli, MD; Jesse Sengillo, MD; and Alexis Warren, MD

11.17.25

The Nuts and Bolts of GA Therapy: Wrapping Up the Conversation

Charles Wykoff, MD, PhD; Sruthi Arepalli, MD; and Kenneth Fan, MD, MBA

11.13.25

AAO '25: GLP-1s and AMD, and Parity in Retina Care

Aleksandra Rachitskaya, MD; and Julia Haller, MD

11.10.25

Late-Breaking Talks at AAO '25: Phase 3 for Uveitic Macular Edema and GATHER2 OLE

Rahul Khurana, MD; and Arshad Khanani, MD, MA

11.06.25

AAO '25: Dry AMD Pipeline and Oral Treatment for Stargardt Disease

Peter Kaiser, MD; and Michel Michaelides, MD

11.03.25

The Nuts and Bolts of GA Therapy: The Discussions Continue

Charles Wykoff, MD, PhD; Hasenin Al-khersan, MD; and Nakul Singh, MD

Show More